635 completed, 332 recruiting, 280 unknown, 128 not yet recruiting. 590 Phase 2, 502 Phase 1, 266 Phase 3, 231 Not applicable, 178 Phase 4.
Follow Injections: new trials by email Literature Review of Injections trials Research Report on Injections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors T320 for Injection - Advanced Solid Tumor (Phase 1) | Phase 1 | Not yet recruiting | Nanolattix Biotechnology Co., Ltd. | 150 | 2027-12-01 | 2026-02-25 |
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| Immersive VR to Reduce Stress, Anxiety, and Pain During PICC/Midline Placement Immersive Virtual Reality, Peripherally Inserted Central Catheter (PICC), Mepivacaine 2% Injection - Vasoconstriction, Biomarkers | Not applicable | Not yet recruiting | diana garcia | 202 | 2027-01-15 | 2026-07-10 |
| Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU - Osteoporosis in Post-menopausal Women | Phase 4 | Not yet recruiting | Sahlgrenska University Hospital | 216 | 2027-01-11 | 2026-08-19 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Gender Affirming Mastectomy Analgesia Rial Paravertebral (single injection), Wide local infiltration - Gender Affirming Surgery, Mastectomy | Not applicable | Not yet recruiting | Nova Scotia Health Authority | 64 | 2027-01-01 | 2026-10-06 |
| Comparing Standard Platelet-Rich Plasma and Light-Enhanced Platelet-Rich Plasma for Treating Hair Loss in Androgenetic Alopecia: A Randomized Controlled Trial Platelet-Rich Plasma (PRP) Injections, Red-light photobiomodulation with cooling, Blue-light photobiomodulation - Androgenetic Alopecia | Early Phase 1 | Not yet recruiting | Kimberly Meathrel | 30 | 2026-12-30 | 2026-07-31 |
| Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A FRSW107 - Severe Hemophilia A | Phase 3 | Not yet recruiting | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 76 | 2026-12-25 | 2024-06-20 |
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients Indigotindisulfonate sodium 0.8% injection - Ureter Injury | Phase 3 | Not yet recruiting | Prove pharm | 18 | 2026-12-01 | 2026-10-16 |
| Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide Fosaprepitant for Injection, Metoclopramide Injection - Nausea and Vomiting, Nausea | Phase 4 | Not yet recruiting | Montefiore Medical Center | 212 | 2026-12-01 | 2026-06-29 |
| Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer EG-007, Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection, Lenvatinib Capsules - Advanced Endometrial Cancer | Phase 3 | Not yet recruiting | Evergreen Therapeutics, Inc. | 450 | 2026-12-01 | 2025-12-08 |
| Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence Recombinant Human Prourokinase for Injection (rhPro-UK), Matching Placebo for Recombinant Human Prourokinase - Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 826 | 2026-12-01 | 2026-10-28 |
| PRP Versus NP Injections for Chronic Discogenic Low Back Pain Platelet-Rich Plasma (PRP) Injection, Nucleus Pulposus (NP) Injection - Discogenic Low Back Pain | Phase 2 / Phase 3 | Not yet recruiting | Walter Reed National Military Medical Center | 60 | 2026-12-01 | 2026-11-02 |
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC LBL-024 for Injection, Etoposide injection, Cisplatin injection - Advanced Extrapulmonary Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2026-11-16 | 2026-10-19 |
| A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC HS-20093 for Injection, ZG006, Adebrelimab Injection - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 338 | 2026-11-15 | 2026-10-23 |
| CYTALUX Dose Extension Study CYTALUX (pafolacianine) injection - Cancer in the Lung, Ovarian Cancer | Phase 4 | Not yet recruiting | On Target Laboratories, LLC | 106 | 2026-11-15 | 2026-11-09 |
| A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 AZD9550 solution for injection, AZD6234 solution for injection, Formulation 1 solution for injection - Healthy Participants | Phase 1 | Not yet recruiting | AstraZeneca | 60 | 2026-11-09 | 2026-11-02 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2 Trastuzumab Rezetecan (SHR-A1811) injection; high dose, Trastuzumab Rezetecan (SHR-A1811) injection; low dose - Advanced Colorectal Cancer Expressing HER2 | Phase 2 | Not yet recruiting | Jiangsu HengRui Medicine Co., Ltd. | 48 | 2026-11-01 | 2026-09-01 |
Showing 20 of 1621. Sign in to see all of them.
Leukemia, Myeloid, Acute (69) · Breast Neoplasms (52) · Carcinoma, Non-Small-Cell Lung (33) · Pain, Postoperative (31) · Myelodysplastic Syndromes (29) · Neoplasms (29) · Prostatic Neoplasms (25) · Ischemic Stroke (24) · COVID-19 (23) · Multiple Myeloma (21) · Recurrence (20) · Stomach Neoplasms (20) · Carcinoma, Hepatocellular (19) · Neoplasm Metastasis (19) · Pain (19)
RemeGen Co., Ltd. (22) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (21) · Jiangsu HengRui Medicine Co., Ltd. (19) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (19) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (18) · Chinese PLA General Hospital (18) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (17) · M.D. Anderson Cancer Center (16) · Nanjing Leads Biolabs Co.,Ltd (16) · Bio-Thera Solutions (15) · National Cancer Institute (NCI) (15) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (14) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (13) · GE Healthcare (12) · Fudan University (9)
China (613) · United States (437) · Canada (66) · France (61) · Germany (50) · Spain (45) · United Kingdom (44) · Australia (41) · South Korea (34) · Egypt (33) · Italy (31) · Turkey (Türkiye) (31) · Netherlands (25) · Poland (24) · Belgium (21)
Jason Wu (11) · Nieto Luis, Master (8) · Dong-Xin Wang, MD, PhD (6) · Weidong Han, Ph.D (6) · Lin Shen (4) · Mark Nestor, MD (4) · Charles Cunningham, PhD (3) · Chunling Jiang, PhD (3) · Hejian Zou (3)
PMID 21482570, PMID 22067185, PMID 23357290, PMID 25487791, PMID 26702925, PMID 29187413, PMID 30597021, PMID 33051668, PMID 33130217, PMID 33208914, PMID 33438477, PMID 34473343, PMID 34487721, PMID 34590307, PMID 34922058, PMID 36184192, PMID 36796484, PMID 37988648, PMID 38008099, PMID 38502709, PMID 38954871, PMID 39468640, PMID 39529079, PMID 41637644, PMID 41940006, PMID 10394018, PMID 10394019, PMID 10740539, PMID 10811675, PMID 10933646, PMID 11020772, PMID 1135616, PMID 11561801, PMID 11704843, PMID 11784875, PMID 11870177, PMID 11981766, PMID 12049862, PMID 12091661, PMID 12145716, PMID 12456412, PMID 12535501, PMID 12540794, PMID 12638566, PMID 12750546, PMID 15007311, PMID 15514282, PMID 15570202, PMID 15808040, PMID 16043828
2023 (8), 2019 (7), P30CA033572 (5), 2025 (4), P30CA015704 (4), 2014 (3), U10CA180886 (3), U10CA180888 (3), UM1CA186712 (3), 2015 (2), 2016 (2), 2017 (2), 2018 (2), P30CA014089 (2), P30CA015083 (2)